1. Shapiro RL, Hatheway C, Swerdlow DL. Botulism in the United States-a clinical and epidemiologic review. Ann Intern Med. 1998;129:221–228. [PubMed] 2. Kessler KR, Benecke R. Botulinum toxin—from poison to remedy. Neurotoxicology. 1997;18:761–770. [PubMed]
3. Springen K, Raymond J, Skipp C, Scelfo JSS. The Botox boom. Newsweek. 2002:50–58.
4. Singh BR. Intimate details of the most poisonous poison. Nat Struct Biol. 2000;7:617–619. [PubMed] 5. Simpson LL. The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol Rev. 1981;33:155–188. [PubMed] 6. Burnett JC, Schmidt JJ, Stafford RG, Panchal RG, Nguyen TL, et al. Novel small molecule inhibitors of botulinum neurotoxin A metalloprotease activity. Biochem Biophys Res Commun. 2003;310:84–93. [PubMed]
7. Park JG, Sill PC, Makiyi EF, Garcia-Sosa AT, Millard CB, et al. Serotype-selective, small-molecule inhibitors of the zinc endopeptidase of botulinum neurotoxin serotype A. Bioorg Med Chem. 2006;14:395–408.
8. Boldt GE, Eubanks LM, Janda KD. Identification of a botulinum neurotoxin A protease inhibitor displaying efficacy in a cellular model. Chem Commun (Camb) 2006:3063–3065. [PubMed] 9. Boldt GE, Kennedy JP, Hixon MS, McAllister LA, Barbieri JT, et al. Synthesis, characterization and development of a high-throughput methodology for the discovery of botulinum neurotoxin a inhibitors. J Comb Chem. 2006;8:513–521. [PMC free article] [PubMed] 10. Boldt GE, Kennedy JP, Janda KD. Identification of a potent botulinum neurotoxin a protease inhibitor using in situ lead identification chemistry. Org Lett. 2006;8:1729–1732. [PMC free article] [PubMed]
11. Dickerson TJ, Janda KD. The use of small molecules to investigate molecular mechanisms and therapeutic targets for treatment of botulinum neurotoxin A intoxication. Chem Biol. 2006;1:359–369.
12. Merino I, Thompson JD, Millard CB, Schmidt JJ, Pang Y-P. Bis-imidazoles as molecular probes for peripheral sites of the zinc endopeptidase of botulinum neurotoxin serotype A. Bioorg Med Chem. 2006;14:3583–3591. [PubMed] 13. Johnson SL, Pellecchia M. Structure- and fragment-based approaches to protease inhibition. Curr Top Med Chem. 2006;6:317–329. [PubMed]
14. Eubanks LM, Hixon MS, Jin W, Hong S, Clancy CM, et al. An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists. Proc Natl Acad Sci U S A 2007
15. Burnett JC, Ruthel G, Stegmann CM, Panchal RG, Nguyen TL, et al. Inhibition of metalloprotease botulinum serotype A from a pseudo-peptide binding mode to a small molecule that is active in primary neurons. J Biol Chem. 2007;282:5004–5014. [PubMed]
16. Arkin MR, Wells JA. Small-molecule inhibitors of protein-protein interactions: progressing towards the dream. Nat Rev Drug Dis. 2004;3:301–317.
17. Breidenbach MA, Brunger AT. Substrate recognition strategy for botulinum neurotoxin serotype A. Nature. 2004;432:925–929. [PubMed]
18. Roe RR, Pang Y-P. Zinc's exclusive tetrahedral coordination governed by its electronic structure. J Mol Model. 1999;5:134–140.
19. Pang YP. Novel zinc protein molecular dynamics simulations: steps toward antiangiogenesis for cancer treatment. J Mol Model. 1999;5:196–202.
20. Pang YP, Xu K, El Yazal J, Prendergast FG. Successful molecular dynamics simulation of the zinc-bound farnesyltransferase using the cationic dummy atom approach. Protein Sci. 2000;9:1857–1865. [PubMed] 21. Pang Y-P. Successful molecular dynamics simulation of two zinc complexes bridged by a hydroxide in phosphotriesterase using the cationic dummy atom method. Proteins. 2001;45:183–189. [PubMed] 22. Oelschlaeger P, Schmid RD, Pleiss J. Insight into the mechanism of the IMP-1 metallo-beta-lactamase by molecular dynamics simulations. Protein Eng. 2003;16:341–350. [PubMed] 23. Oelschlaeger P, Schmid RD, Pleiss J. Modeling domino effects in enzymes: molecular basis of the substrate specificity of the bacterial metallo-beta-lactamases IMP-1 and IMP-6. Biochemistry. 2003;42:8945–8956. [PubMed]
24. Pang YP, Miller JL, Kollman PA. Computational and experimental studies of (2,2)-bis(indol-1-yl-methyl)acetate suggest the importance of the hydrophobic effect in aromatic stacking interactions. J Am Chem Soc. 1999;121:1717–1725.
25. Jorgensen WL, Chandreskhar J, Madura JD, Impey RW, Klein ML. Comparison of simple potential functions for simulating liquid water. J Chem Phys. 1982;79:926–935.
26. Miyaura N, Suzuki A. Stereoselective synthesis of arylated (E)-alkenes by the reaction of alk-1-enylboranes with aryl halides in the presence of palladium catalyst. J Chem Soc, Chem Commun. 1979:866–867.
27. Suzuki A. Synthetic studies via the cross-coupling reaction of organoboron derivatives with organic halides. Pure Appl Chem. 1991;63:419–422.
28. Miyaura N, Suzuki A. Palladium-catalyzed cross-coupling reactions of organoboron compounds. Chem Rev. 1995;95:2457–2483.
29. Joule JA, Mills K, Smith GF. Cheltenham: Stanley Thornes; 1998. Heterocyclic Chemistry. p. 261.
30. Gupta RR, Kumar M, Gupta V. Berlin: Springer; 1999. Heterocyclic Chemistry. Volume II. pp. 145–147.
31. Dieck HA, Heck FR. Palladium catalyzed synthesis of aryl heterocyclic and vinylic acetylene derivatives. J Organomet Chem. 1975;93:259–263.
32. Sakai N, Annaka K, Konakahara T. Palladium-catalyzed coupling reaction of terminal alkynes with aryl iodides in the presence of indium tribromide and its application to a one-pot synthesis of 2-phenylindole. Org Lett. 2004;6:1527–1530. [PubMed] 33. Meegalla SK, Doller D, Sha D, Soll R, Wisnewski N, et al. Synthesis and GABA receptor potency of 3-thiomethyl-4-(hetero)aryl-5-amino-1-phenylpyrazoles. Bioorg Med Chem Lett. 2004;14:4949–4953. [PubMed] 34. Ho CY, Strobel E, Ralbovsky J, Galemmo RA., Jr Improved solution- and solid-phase preparation of hydroxamic acids from esters. J Org Chem. 2005;70:4873–4875. [PubMed]
35. Mootoo DR, Fraiser-Reid B. n-Pentenyl 2-amino-2-deoxy glycosides undergo stereoselective coupling under mild, chemospecific conditions. Tetrahedron Lett. 1989;30:2363.
36. Ariffin A, Khan MN, Lan LC, May FY, Yun CS. Suggested improved method for the Ing-Manske and related reactions for the second step of Gabriel synthesis of primary amines. Synth Commun. 2004;34:4439–4445.
37. Schmidt JJ, Bostian KA. Endoproteinase activity of type A botulinum neurotoxin: substrate requirements and activation by serum albumin. J Protein Chem. 1997;16:19–26. [PubMed] 38. Todhunter JA. Reversible enzyme inhibition. Methods in Enzymology. 1979;63:383–411. [PubMed] 39. Shapiro R, Riordan JF. Inhibition of angiotensin converting enzyme: mechanism and substrate dependence. Biochemistry. 1984;23:5225–5233. [PubMed] 40. Pang Y-P, Quiram P, Jelacic T, Hong F, Brimijoin S. Highly potent, selective, and low cost bis-tetrahydroaminacrine inhibitors of acetylcholinesterase: steps toward novel drugs for treating Alzheimer's disease. J Biol Chem. 1996;271:23646–23649. [PubMed] 41. Pang Y-P. Nonbonded bivalence approach to cell-permeable molecules that target DNA sequences. Bioorg Med Chem. 2004;12:3063–3068. [PubMed]
42. El Yazal J, Pang YP. Ab initio calculations of proton dissociation energies of zinc ligands: hypothesis of imidazolate as zinc ligand in proteins. J Phys Chem B. 1999;103:8773–8779.
43. El Yazal J, Roe RR, Pang Y-P. Zinc's affect on proton transfer between imidazole and acetate predicted by ab initio calculations. J Phys Chem B. 2000;104:6662–6667.
44. El Yazal J, Pang YP. Comparison of DFT, Moller-Plesset, and coupled cluster calculations of the proton dissociation energies of imidazole and N-methylacetamide in the presence of zinc(II). J Mol Struct (Theochem), 2001;545:271–274.
45. Pearlman DA, Case DA, Caldwell JW, Ross WS, Cheatham TE, III, et al. AMBER, a package of computer programs for applying molecular mechanics, normal mode analysis, molecular dynamics and free energy calculations to simulate the structural and energetic properties of molecules. Comput Phys Commun. 1995;91:1–41.
46. Frisch MJ, Trucks GW, Schlegel HB, Gill PMW, Hohnson BG, et al. Pittsburgh, PA: Gaussian, Inc; 1999. GAUSSIAN 98, Revision A.7.
47. Pang Y-P. Three-dimensional model of a substrate-bound SARS chymotrypsin-like cysteine proteinase predicted by multiple molecular dynamics simulations: catalytic efficiency regulated by substrate binding. Proteins. 2004;57:747–757. [PubMed]
48. Cornell WD, Cieplak P, Bayly CI, Gould IR, Merz KM, Jr, et al. A second generation force field for the simulation of proteins, nucleic acids, and organic molecules. J Am Chem Soc. 1995;117:5179–5197.
49. Berendsen HJC, Postma JPM, van Gunsteren WF, Di Nola A, Haak JR. Molecular dynamics with coupling to an external bath. J Chem Phys. 1984;81:3684–3690.
50. Darden TA, York DM, Pedersen LG. Particle Mesh Ewald: An N log(N) method for Ewald sums in large systems. J Chem Phys. 1993;98:10089–10092.
51. Shone CC, Roberts AK. Peptide substrate specificity and properties of the zinc-endopeptidase activity of botulinum type B neurotoxin. Eur J Biochem. 1994;225:263–270. [PubMed] 52. Schmidt JJ, Stafford RG. Fluorigenic substrates for the protease activities of botulinum neurotoxins, serotypes A, B, and F. Appl Environ Microbiol. 2003;69:297–303. [PMC free article] [PubMed]